Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0284979 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Aya Kamimura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Central Serous Chorioretinopathy, Photochemotherapy, Choroidal Neovascularization. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To compare the two-year outcome of half-time photodynamic therapy (htPDT) in chronic central serous chorioretinopathy (cCSC) with and without choroidal neovascularization (CNV).
Methods
In this retrospective study, we included 88 eyes of 88 patients with cCSC who underwent htPDT and were followed up for more than 24 months. Patients were divided into two groups with (21 eyes) or without (67 eyes) CNV before htPDT treatment. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SCT), and the presence of subretinal fluid (SRF) were evaluated at baseline and at 1, 3, 6, 12, and 24 months after PDT.
Results
A significant intergroup difference was noted in terms of age ( P = 0.038). Significant improvements in the BCVA and SCT were found at all time points in eyes without CNV but only at 24 months in eyes with CNV. CRT was significantly reduced in both groups at all time points. No significant intergroup differences were noted in terms of BCVA, SCT and CRT at all time points. There were significant differences in the rate of recurrent and persistent SRF between groups (22.4% (without CNV) vs. 52.4% (with CNV), P = 0.013, and 26.9% (without CNV) vs. 57.1% (with CNV), P = 0.017, respectively). The presence of CNV was significantly associated with the recurrence and persistence of SRF after initial PDT (P = 0.007 and 0.028, respectively). Logistic regression analyses showed that the baseline BCVA, and not the presence of CNV, was significantly associated with BCVA at 24 months after initial PDT (P < 0.01).
Conclusions
A htPDT for cCSC was less effective in eyes with CNV than in those without CNV regarding the recurrence and persistence of SRF. Additional treatment might be required in eyes with CNV during 24-month follow-up periods.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Ophthalmology, Department of Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
- Department of Ophthalmology, Kobe City Eye Hospital, Kobe, Hyogo, Japan.
ORCID-Profile: Akiko Miki
Zitieren
APA
Kamimura, A., Miki, A., Kishi, M., Okuda, M., Hayashida-Hirano, M., Sakamoto, M., Matsumiya, W., Imai, H., Kusuhara, S., & Nakamura, M. (2023). Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization. PLOS ONE. https://doi.org/10.1371/journal.pone.0284979
Vancouver
Kamimura A, Miki A, Kishi M, Okuda M, Hayashida-Hirano M, Sakamoto M, et al. Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization. PLOS ONE. 2023. doi:10.1371/journal.pone.0284979
BibTeX
@article{Kamimura2023,
author = {Kamimura, Aya and Miki, Akiko and Kishi, Maya and Okuda, Mina and Hayashida-Hirano, Mayuka and Sakamoto, Mari and Matsumiya, Wataru and Imai, Hisanori and Kusuhara, Sentaro and Nakamura, Makoto},
title = {Two-year outcome of half-time photodynamic therapy for chronic central serous chorioretinopathy with and without choroidal neovascularization},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0284979}
}
EUVIMED